Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06345729
Status:
RECRUITING
Last Update Posted:
2024-07-12
First Post:
2024-03-28
Brief Title:
A Study of MK-1084 Plus Pembrolizumab MK-3475 in Participants With KRAS G12C Mutant Metastatic Non-small Cell Lung Cancer NSCLC With Programmed Cell Death Ligand 1 PD-L1 Tumor Proportion Score TPS 50 MK-1084-004
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC